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Key points 
1. Rituximab treatment results in loss of human germinal center B cells 
2. Human T follicular helper and T follicular regulatory cells do not require 
germinal center B cells for their maintenance 
Abstract  
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The monoclonal anti-CD20 antibody rituximab depletes B cells in the treatment of 
lymphoma and autoimmune disease, and contributes to alloantibody depletion in 
transplantation across immunological barriers. The effects of rituximab on T cells are 
less well described. T follicular helper cells (Tfh) provide growth and differentiation 
signals to germinal centre (GC) B cells to support antibody production, and 
suppressive T follicular regulatory cells (Tfr) regulate this response.  In mice, both 
Tfh and Tfr are absolutely dependent on B cells for their formation and on the GC for 
their maintenance.  Here, we demonstrate that rituximab treatment results in a lack of 
GC B cells in human lymph nodes without affecting the Tfh or Tfr cell populations.  
These data demonstrate that human Tfh and Tfr do not require an on-going GC 
response for their maintenance.  The persistence of Tfh and Tfr in following rituximab 
treatment may permit rapid reconstitution of the pathological GC response once the 
B cell pool begins to recover.  Strategies for maintaining remission after rituximab 
therapy will need to take this persistence of Tfh into account. 
 
Introduction 
In response to infection or immunization with a T-dependent antigen, germinal 
centers (GC) form within the B cell follicles of secondary lymphoid tissues1. GC are 
clusters of rapidly dividing B cells that are undergoing rounds of somatic 
hypermutation of their antigen receptor genes. This process of somatic 
hypermutation is random; therefore, in order to improve the affinity of cells that exit 
the GC as differentiated cells, selection needs to occur. B cells compete with each 
other for T cell help within the GC; B cells with high-affinity for antigen can 
outcompete lower affinity B cells for T cell help.  Those B cells that receive help 
differentiate into antibody secreting plasma cells and memory B cells2-4. T cell help 
within the GC is provided by a subset of CD4+ T cells, T follicular helper cells (Tfh). 
Tfh are a specialized subset of CD4+ helper T cells that migrate into GC and provide 
help and survival signals to GC B cells, promoting their differentiation into long-lived 
plasma or memory B cells5,6. T cell help is essential for the formation and 
maintenance of the GC and the response collapses in the absence of Tfh7. The 
survival signals provided by Tfh to those GC B cells with the highest affinity BCR 
allow these B cell clones to proliferate and differentiate to become the predominant 
antibody producing cells8. Tfh are required for the response to foreign antigens, but 
in excess they can support autoreactive GC responses, leading to autoimmunity9,10. 
In addition to Tfh, there is another subset of CD4+ T cells within the GC, follicular 
regulatory T (Tfr) cells, which has been characterized by our group and others11-13. 
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Tfr cells share phenotypic characteristics with Tfh but are derived from suppressive 
Foxp3+ regulatory T cells (Tregs). Tfr co-opt aspects of the Tfh differentiation 
pathway and upregulate B-cell lymphoma – 6 (Bcl6), the transcriptional repressor 
that is essential for the formation of Tfh11,14-16. This allows Tfr to enter the GC and 
exert a suppressive function. Within the GC, Tfr cells control the size of the GC 
response and restrict the outgrowth of non-antigen specific B cell clones11-13.  
The formation of Tfh and Tfr is dependent on interactions with B cells outside the B 
cell follicle. Recent data suggests that the initial step in the formation of Tfh is 
upregulation of the achaete-schute homologue 2 (Ascl2)17. This transcription factor 
induces upregulation of the chemokine receptor CXCR5, the ligand of which, 
CXCL13, is expressed in the B cell follicle, enabling pre-Tfh to migrate to the border 
of the B cell follicle. Ascl2 has also been shown to suppress genes associated with 
other T cell subsets, priming pre-Tfh differentiation down the follicular pathway17. Pre-
Tfh cells also express Bcl-6, which is both necessary and sufficient for Tfh 
differentiation14-16. In contrast with the role for Ascl-2 in Tfh cells, Tfr cells require 
NFAT2 for upregulation of CXCR5 and their subsequent migration18. At the T-B 
border Tfh precursors encounter antigen primed B cells, and receive a second round 
of antigen presentation, enabling them to stabilize Bcl-6 expression, commit to 
becoming a Tfh cell and migrate into the GC19,20. In return, pre-Tfh provide signals to 
B cells to initiate immunoglobulin isotype class switching and form GCs21. In mice, it 
is clear that the interactions between Tfh, Tfr and GC B cells are reciprocal. Tfh and 
Tfr both require on-going interactions with GC B cells in order to maintain their 
phenotype and function, and selective lack of GC B cells during an on-going 
response leads to a reduction in Tfh numbers22. Equally, GC B cell numbers and 
differentiation depend on support from Tfh, with the GC response collapsing in the 
absence of Tfh11-13,22.  
Translating the extensive knowledge of mouse Tfh and Tfr biology into humans has 
been difficult, in part because obtaining normal human secondary lymphoid tissue is 
not straightforward, but also because manipulation of the immune responses in 
humans is rarely possible. In humans, both Tfh and Tfr have been identified in 
tonsillar GCs, but description of their development and function has been limited12,23-
26. Here we have taken advantage of the use of the B cell depleting anti-CD20 
monoclonal antibody rituximab27 prior to renal transplantation to assess the effects of 
this treatment on lymph node GC, Tfh and Tfr cells, and their circulating 
counterparts.  
Because of the limited access to secondary lymphoid tissues from humans, several 
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groups have examined circulating cells expressing the same surface markers as Tfh, 
in particular CXCR5, ICOS and PD-1, coined circulating Tfh-like cells (cTfh), that can 
act as a biomarker for Tfh differentiation in the secondary lymphoid tissues25,28-30.  
cTfh numbers are elevated in patients with autoimmune diseases such as systemic 
lupus erythematosus31 and rheumatoid arthritis32 and appear to correlate with 
increased antibody levels and disease severity. Circulating Tfh-like cells appear to be 
a population of memory T cells that are generated during Tfh differentiation.  Tfh-like 
cells do not express Bcl-6 but are able to quickly differentiate into cells capable of 
supporting antibody production25,28-30. In order to compare circulating Tfh-like cells 
with tissue resident cells, we have obtained paired blood and tissue samples from 
patients immediately prior to renal transplantation, who have been screened to 
exclude concurrent infection or malignancy. Some patients undergoing 
transplantation will have pre-formed antibodies directed against donor antigens, 
donor specific antibodies (DSA)33. These can be antibodies against blood group 
antigens, or anti-HLA antibodies formed from sensitizing events such as pregnancy. 
To reduce antibody titers and allow ABO or HLA incompatible transplantation, 
patients can undergo “desensitization” regimens33, often including the anti-CD20 
monoclonal antibody rituximab27. Rituximab provides rapid and profound depletion of 
circulating B cells, although pre-B and mature plasma cells do not express CD20 and 
are thus preserved34. In our center, rituximab is given a month before transplantation 
along with tacrolimus and mycophenolate mofetil (MMF), then followed with five 
sessions of plasma exchange with the aim of reducing DSA titers by targeting both 
the antibodies themselves and the cells producing them. 
We have taken advantage of the rituximab treatment regimen to examine the 
importance of B cells in maintaining the Tfh and Tfr populations in human lymph 
nodes.  We show that rituximab in combination with tacrolimus and MMF is an 
efficient treatment for removing circulating naïve B cells, but not memory B cells, and 
surprisingly does not significantly alter the number of lymph node B cells. However, 
rituximab in combination with tacrolimus and MMF leads to an absence of GC B cells 
in the lymph node of treated patients. Strikingly, despite the lack of GC B cells, Tfh 
and Tfr are still present, suggesting that, contrary to reports in the mouse, human Tfh 
and Tfr cells do not require the GC B cell niche for their maintenance. 
Patients and Methods 
Patients 
This study received ethical approval from the Local Research Ethics Committee. 
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Patients were recruited from the renal transplant live-donor programme, and 
provided informed consent to participation. 26 patients provided paired blood and 
tissue samples, 9 women and 17 men. Mean age was 46 (18-69). All patients were 
either receiving or within 6 months of requiring renal replacement therapy. Patients 
taking immunosuppressive medication prior to transplant were excluded, except for 
those undergoing planned desensitization.  
Patients undergoing desensitization therapy (n=5) received 500mg of the anti-CD20 
monoclonal antibody rituximab one month before transplantation, followed by 
tacrolimus (dose adjusted for each patient aiming for blood levels 5-15ng/ml), and 
mycophenolate mofetil (MMF) 1g twice daily. All patients underwent antibody 
removal with plasma exchange for 5 sessions prior to transplantation, which went 
ahead only if antibody levels were within locally acceptable limits.  
50mls of blood was taken at the time of transplant.  Lymphoid tissue was removed to 
allow access to iliac vessels as part of the routine operative procedure.  
Sample preparation 
Blood samples were prepared as previously described35. Lymph node samples were 
made into a single cell suspension and stained for flow cytometry as previously 
described11. 
Antibodies  
Anti-human CD45RA clone HI100 (eBioscience), CD127 clone eBioRDR5 
(eBioscience), CXCR3 clone IC6 (BD), FoxP3 clone PCH101 (eBioscience), CCR6 
cloneR6H1 (eBioscience), BCL-6 clone K112-91 (BD), CD57 clone NK-1 (BD), CD4 
clone OKT4 (eBioscience), CXCR5 clone RF8B2 (BD) CD20 clone 2H7 
(eBioscience), CD19 clone SJ25C1 (eBioscience), CD38 clone HIT2 (BD), IgD clone 
1A6-2 (BD), CD27 clone O323 (eBioscience) and Streptavidin AF780 (eBioscience). 
Tfh, Tfr and B cell co-cultures 
CD19+CD27+IgD- B cells, CXCR5+CD57+CD25-CD4+ Tfh cells and 
CXCR5+CD57+CD127-CD25+CD4+ Tfr cells were flow-sorted from iliac lymph nodes 
and then cultured in 96-well U-bottom tissue culture plates (1x104 of each cell type 
per well) in the presence of T cell activation and expansion beads (Miltenyi, as per 
manufacturers instructions). IgA secretion was determined after 5 days by ELISA. 
IgA ELISA 
Secretion of IgA was determined by Ig H chain-specific enzyme-linked 
 6 
immunosorbent assay.  Nunc MaxiSorp® flat-bottom 96 well plate (eBioscicence) 
were coated with goat anti-human IgA (Jackson ImmunoResearch). Nonspecific 
binding sites were blocked with 1% BSA/PBS. Culture supernatants were added to 
the wells and incubated for 2 h at 37°C.  Plates were washed before adding HRP-
conjugated donkey anti-human Ig H+L chain (Jackson ImmunoResearch). Bound IgA 
was visualized with TMB substrate (BioLegend).  
Statistical analysis 
Statistical analysis was performed using Prism software package using Mann-
Whitney testing. Absolute cell counts for peripheral blood samples were calculated 
from hospital laboratory lymphocyte counts taken at the same time point as 
sampling. Absolute cell counts for lymph nodes were calculated from total cell count 
obtained at the time of processing the lymph node to form a single cell suspension. 
 
Results 
Rituximab effectively removes naïve circulating B cells but not memory B cells.  
The impact of rituximab on peripheral and tissue resident B cells has been of 
considerable interest since this B cell-depleting therapy has been shown to be 
efficacious in treating hematological malignancies and autoimmune diseases. Many 
studies have examined the effect of both single and multiple doses of rituximab and 
shown variable removal of different B cell subsets36-40. Here, we compared blood and 
lymph node samples from patients receiving a 500mg dose of rituximab (RTX) one 
month prior to antibody-incompatible kidney transplantation, with those from patients 
not receiving rituximab (no RTX). This single dose effectively removed CD20+ B cells 
within the peripheral blood, although a proportion of CD19+CD20- B cells were still 
detectable (Figure 1A-C). We characterised these cells in more detail using flow 
cytometry to divide them into IgD+CD27- naïve B cells, IgD+CD27+ memory cells, IgD-
CD27+ memory cells, IgD-CD27- cells and IgD-CD27hiCD38hi plasma cells. There 
were differences in these subsets between untreated patients (Fig 1D) and those 
who had received rituximab (Fig 1E). In particular we found that naïve, IgD+ memory 
and plasma cells were significantly reduced in rituximab treated patients compared to 
control (Figs 1F-H). In contrast, IgD- memory and IgD-CD27- cells showed relative 
preservation (Figs 1I, 1J), consistent with previous reports41-43.  IgD-CD27- cells have 
previously been characterised as IgG-CD27- memory B cells44 suggesting that the 
memory B cell population in the peripheral blood is not as severely affected following 
rituximab treatment as naïve B cells. Interestingly, these memory B cell populations 
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are reduced in the peripheral blood of patients with end-stage renal failure compared 
to healthy controls (Supplementary figure 1). 
 
Tissue resident B cells are more resistant to removal by rituximab 
Flow cytometric analysis of lymphocytes from iliac lymph nodes showed no reduction 
in the number of CD19+CD20+ B cells in rituximab-treated patients compared to 
controls (Figure 2A-C). This relative preservation of tissue B cells has been 
previously described43. However, we noted a complete absence of CD38hiBcl6+ GC B 
cells in rituximab-treated patients (Figure 2D-F). CD38hiBcl6+ GC B cells in untreated 
patients expressed higher levels of CD20 (Figure 2G) compared to CD38loBcl6- B 
cells, suggesting they might be preferential targets for rituximab-mediated removal.  
Having said that, whether this loss of GC B cells is due to direct depletion by 
rituximab, or is indirect and due, for example, to a failure of GC generation secondary 
to loss of a pre-GC B cell population, cannot be determined from these data. These 
data show that rituximab, in combination with tacrolimus and MMF, has no overall 
effect on B cell numbers in the iliac lymph node, but GC B cells are not detectable 
following this treatment combination.  
 
Memory B cells are preserved in the lymph nodes of rituximab treated patients 
Despite the preservation of total B cell number in the lymph node compared to 
peripheral blood we assessed whether there was a change in the composition of the 
B cell population following rituximab treatment.  We compared B cell subsets in the 
lymph node between untreated (Fig 3A) and rituximab treated (Fig 3B) patients, as 
we had previously in the blood (Figure 1). There was a significant reduction in 
IgD+CD27- naïve B cells and IgD+CD27+ memory cells in rituximab treated patients 
and controls (Figs 3C, 3D), together with preservation of IgD-CD27+ memory and IgD- 
CD27- cells in the lymph node (Figs 3E, 3F) of both patient groups. We did not find a 
reduction in IgD-CD27hiCD38hi plasma cells in the lymph node, consistent with their 
low expression of CD20 (Fig 3G). In addition, rituximab treated patients had an 
unusual population of CD19loCD20lo cells, which consisted largely of memory B cells 
(Fig 3H).  
 
Loss of the GC after rituximab treatment did not reduce Tfh within the lymph node. 
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In mice there is a positive correlation between the number of GC B cells and the 
number of Tfh cells45, because Tfh maintenance requires sustained antigenic 
stimulation from GC B cells22.  We were therefore interested in whether the lack of 
GC B cells in rituximab treated patients reduced GC Tfh numbers. Although CXCR5 
and ICOS are routinely used to identify T cells with B helper capacity, we were 
specifically interested in those T cells that would be located within the GC. CD57 has 
been shown to be a marker of T cells within the GC, and CXCR5+CD57+CD4+ T cells 
have been demonstrated to be Tfh in both phenotype and function45. Surprisingly, 
there was no difference in the proportion or total number of CXCR5+CD57+CD4+ Tfh 
between rituximab-treated patients and controls (Figure 4A-C). Tfh can be divided 
into Th1-like, Th2-like and Th17-like subsets, each with different capacity for B cell 
help29. To determine if loss of the GC affected these Tfh subsets differentially we 
divided cells into CXCR3+CCR6-Th1-like Tfh, CXCR3-CCR6-Th2-like Tfh and 
CXCR3-CCR6+Th17-like Tfh. We found no differences in these subsets in rituximab-
treated patients. (Figure 4D, E).  Furthermore, we did not see any alteration in the 
circulating CXCR5+CD4+ Tfh-like population in the blood of the same patients (Figure 
4F, G). These data suggest that rituximab treatment does not reduce GC Tfh in 
humans, despite completely eliminating GC B cells. 
 
Rituximab did not alter Tregs or Tfr numbers within the lymph node. 
Suppressive Tfr cells have been previously described within the GC11-13. These cells 
derive from Foxp3+ precursors, and in mice are absolutely dependent on B cells and 
the GC for their formation11,12,46. Rituximab has been described to alter proportions 
and function of Tregs in humans47,48; we therefore determined whether either the total 
Treg pool or the Tfr subset was altered after rituximab treatment. There was no 
difference in FOXP3+CD127-CD4+ Treg in the lymph node (Figure 5A-C) or 
CXCR5+CD57+FOXP3+CD127-CD4+ Tfr cells (Figure 5D-F), between treated and 
untreated patients, suggesting that maintenance of the Tfr cell pool does not require 
an on-going GC response in humans. To confirm that CXCR5+CD57+FOXP3+CD127-
CD4+ Tfr cells function as suppressors of B cell responses, we performed co-culture 
assays of Tfh cells (CXCR5+CD57+CD25-CD4+) with memory B cells (CD27+IgD-
CD19+) in the presence or absence of CXCR5+CD57+CD25+CD127-CD4+ Tfr cells.  
Tfr cells inhibited the production of T-dependent IgA by memory B cells after five 
days of culture (Figure 5G).  Together, these data demonstrate that these cells have 
a surface phenotype and function consistent with Tfr cells, and they do not require an 
on-going GC for their maintenance. 
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Discussion 
In this study we show that rituximab treatment combined with tacrolimus and MMF 
led to a profound reduction in the numbers of circulating naïve and IgD+ memory B 
cells with relative preservation of IgD-CD27+ memory B cells, which has been well 
described in previous studies43,49. The effects of rituximab on tissue resident cells 
have been investigated and it is clear that even a complete lack of circulating cells 
does not necessarily reflect deficiency of these cells in the tissues49,50. In our cohort, 
rituximab, in combination with tacrolimus and MMF, did not reduce the total B cell 
numbers in the lymph node, but did result in the absence of CD38hiBcl6+CD19+ GC B 
cells and CD19+IgD+ naïve B cells, while leaving the CD27+CD19+ memory B cell 
compartment intact. Although loss of GC B cells by this treatment has not been 
described in humans previously, it has been suggested that rituximab can reduce the 
number of GC B cells in cynomolgus monkeys, based on an altered histological 
appearance of follicles with a reduction in the number of CD19+ cells, rather than 
using specific GC markers49.  
Consistent with previous reports showing variable but incomplete depletion of B cells 
in lymph nodes, we found no significant reduction in the number of B cells in the 
lymph node40,43,50,51. However we did find a significant reduction in the number of 
naïve and IgD+ memory cells in the lymph node, consistent with changes observed in 
the peripheral blood, though less profound. The residual cells in the lymph node 
showed a higher proportion of IgD-CD27+ memory B cells and IgD-CD27- memory B 
cells, which have been previously described as being resistant to removal by one 
dose of rituximab43. The mechanism by which memory cells are resistant to removal 
by one dose of rituximab is unclear, although several have been postulated. B cell 
depletion by rituximab is dependent on antibody-dependent cellular cytotoxicity 
(ADCC), thus anatomical variation in Fc receptor expression may limit cell depletion, 
and an FcRIIIa polymorphism has been associated with poor response to rituximab 
in lymphoma patients52. However, there is little evidence addressing which 
mechanisms predominate outside the setting of hematological malignancies, where 
there is derangement of the normal environment including depletion of complement 
and proportionately low numbers of effector cells, due to the expansion of malignant 
cells, thus limiting ADCC52. 
We did not find a reduction in the number of plasma cells in the lymph node, which 
do not express CD20 and are therefore not targeted by rituximab. The absence of 
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plasmablasts in the peripheral blood of rituximab treated patients may reflect the 
absence of an on-going GC response due to the lack of GC B cells, as circulating 
plasma cells are short lived outside of their bone marrow niche53. 
The effects of rituximab on T cells have been long debated, with suggestions that 
regulatory T cell numbers and function may be increased following rituximab 
treatment for autoimmune diseases47,48,54 but other group have described reductions 
in Treg numbers37. Alterations in other subsets of CD4 T cells have also been 
suggested47, however despite these previous findings, and the absence of GC B 
cells in all rituximab treated patients we found no alterations in Tfh or Tfr cell 
numbers. This observation is in contrast to what has observed in mice, where 
depletion of GC B cells results in the loss of Tfh cells22.  However, data from patients 
with X-linked agammaglobulinaemia, who have an almost complete arrest of B cell 
differentiation in the bone marrow resulting in very few peripheral B cells, have a 
markedly reduced population of peripheral blood cTfh cells compared to healthy 
controls55, consistent with a failure of formation, or maintenance, of Tfh in the 
absence of B cells in humans.  Taken together with our observations, this suggests 
that, in humans, B cells are required for Tfh formation, but the GC is not necessary 
for their maintenance. 
That on-going interactions with GC B cells are dispensable for the persistence of GC-
T cells may occur because human Tfh and Tfr can be maintained without interactions 
with B cells, or that such interactions can be provided by non-GC B cells, such as the 
memory B cells we show persist despite rituximab therapy.  Either of these 
possibilities is intriguing, the latter because the maintenance of GC-T cells by 
memory B cells has not been described in humans or mice previously. It has, 
however, been suggested that memory B cells are able to support lymph-node 
resident memory Tfh-like cells in mice56,57, raising the possibility that the Tfh cells 
identified in this study may represent a lymphoid reservoir of memory Tfh cells similar 
to those described in mice56, rather than a bona fide effector population. This seems 
unlikely, however, as CD57+CXCR5+CD4+ cells are prone to apoptosis58, which is not 
a characteristic of persisting memory cells.  
Alternatively, it is possible that our assessment at a single time point reflects 
repopulation of cells from circulating Tfh-like cells, rather than persistence despite an 
absence of GC cells. This would seem unlikely, however, as it would involve 
migration and de novo differentiation of lymph node Tfh and Tfr cell populations in 
the absence of a GC response. 
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Because of the absence of GC B cells and the reports that rituximab can distort 
follicular architecture49, we have used CD57 as a marker of GC-Tfh cells, in 
combination with the Tfh/Tfr surface receptor CXCR5. Although the function of CD57 
on Tfh cells is not well understood, it is clear that it identifies the GC-located Tfh 
cells59.  It has been shown that CXCR5+CD57- cells have similar B helper capacity to 
CXCR5+CD57+ cells in vitro and that ICOS expression is more important for the 
identification of cells that can support antibody production60. CXCR5 and ICOS have 
therefore become the classical markers used to identify cells with effector Tfh 
function, which may reflect GC-Tfh and Tfh cells that act to support antibody 
production outside the follicle. It has also been shown that CXCR5+CD57+ cells are 
Tfh, located in the GC and expressing ICOS and Bcl6, the key transcription factor for 
Tfh differentiation45,61.  
Whether these cells are effector or memory populations, the preservation of these 
Tfh and Tfr cells following rituximab, tacrolimus and MMF treatment, is likely to result 
in the persistence of T cells that are able to support an allo- or autoreactive B cell 
response once the B cell pool recovers.  Consistent with this, after a single dose of 
rituximab to treat autoimmunity, disease flare and autoantibody production are 
common after repopulation of the B cell pool42,62,63. Together, our results suggest that 
additional treatment targeting Tfh may be required to reduce relapse risk following 
rituximab treatment for autoimmune disease or in the setting of antibody incompatible 
transplantation.  
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Figure legends 
 
Figure 1: Rituximab effectively depletes naïve circulating B cells but not 
memory B cells (A) Flow cytometric contour plots of CD19 and CD20, and numbers 
of CD20+ B cells (B), CD19+ B cells (C) on peripheral blood lymphocytes taken from 
patients that have not (control patients, top) or have (lower) been treated with 
rituximab. D) Flow cytometric contour plot of naïve, IgD+ memory, IgD- memory, 
plasma cell and CD27-IgD- subsets of CD19+ cells and MFI of CD38 on these 
subsets in a representative untreated patient. E) Flow cytometric contour plot and 
MFI of CD38 of the same subsets in a representative rituximab treated patient. Bar 
graphs of peripheral blood IgD+CD27-CD19+ naïve B cells (F) IgD+CD27+CD19+ 
memory B cells (G), CD38hiIgD-CD27hiCD19+ plasma (H), IgD-CD27+CD19+ memory 
B cells (I) and cells IgD-CD27-CD19+ B cells (J). For all bar graphs one symbol 
represents one individual, and the height of the bar represents the mean. 
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Figure 2: GC B cells are not detectable after rituximab treatment. (A) Contour 
plots of CD19 and CD20 on lymphocytes from iliac lymph node of rituximab treated 
patients and controls.  The number (B) and proportion (C) of CD20+ B cells in the 
lymph nodes of rituximab treated patients and controls.  Contour plots (D), the 
percentage (E) and total number (F) of CD38+Bcl-6+CD19+ GC B cells in the lymph 
nodes of rituximab treated patients and controls.  (G) Mean fluorescence intensity of 
CD20 on CD38-Bcl-6- non-GC B cells and CD38+Bcl-6+ GC B cells from control 
patients. (H) Mean fluorescence intensity of CD20 on CD19+ lymph node B cells from 
rituximab treated patients and controls. In bar graphs, one symbol represents one 
individual, and the height of the bar represents the mean. 
 
Figure 3: Characterisation of CD19+ B cells in the lymph node suggests the 
cells resistant to removal are memory cells. Contour plots of cell subsets and MFI 
of CD38 on CD19+ cells from iliac lymph nodes of controls (A) and rituximab treated 
patients (B). Bar graphs of lymph node CD27-IgD+CD19+ naïve B cells (C) 
CD27+IgD+CD19+ memory B cells (D), CD27hiCD38hiIgD-CD19+ plasma cells (E), 
CD27+IgD-CD19+ memory B cells (F) and CD27-IgD-CD19+ B cells (G). For all bar 
graphs one symbol represents one individual, and the height of the bar represents 
the mean. (H) Detailed analysis of CD19loCD20lo cells alone in rituximab treated 
patients.  
 
Figure 4: Loss of the GC after rituximab treatment did not reduce Tfh numbers 
in the lymph node or peripheral blood. Flow cytometric contour plots (A), 
proportion (B) and total number (C) of CXCR5+CD57+CD4+Tfh from iliac lymph nodes 
taken prior to kidney transplantation in rituximab-treated patients and controls.  
Contour plots (D) and quantitation (E) of CXCR3+CCR6-Th1-like Tfh (top left 
quadrant gate, panel D), CXCR3-CCR6-Th2-like Tfh (lower left quadrant gate, panel 
D) and CXCR3-CCR6+Th17-like lymph node Tfh cells (lower right quadrant gate, 
panel D). Contour plots (F) and bar graphs (G) of peripheral blood CXCR5+CD4+ Tfh-
like cells from the same patients in A-E.  In graphs, one symbol represents one 
individual, the height of the bar represents the mean.  
 
Figure 5: Rituximab did not alter Treg or Tfr numbers within the lymph node.  
Flow cytometric contour plots (A) and quantitation of the proportion (B) and total 
number (C) of FOXP3+CD127-CD4+Treg from iliac lymph nodes taken prior to kidney 
transplantation in rituximab-treated patients and controls.  Contour plots (D), 
proportion (E) and total number (F) of CXCR5+CD57+FOXP3+CD127-CD4+Tfr from 
iliac lymph nodes. In graphs, one symbol represents one individual, and the height of 
the bar represents the mean. (G) IgA production in CD19+CD27+IgD- B cells cultured 
alone, co-culture of B cells with CXCR5+CD57+CD25-CD4+ Tfh cells or co-culture of B 
cells with Tfh and CXCR5+CD57+CD127-CD25+CD4+Tfr flow-sorted from iliac lymph 
nodes.  Data in (G) are a representative biological replicate of three independent 
biological replicates.  Height of the bars represent the mean of 4 technical replicates, 
and the error bars show the standard deviation (n.d. = not detected above 
background). 
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